Cardinal Health (CAH)
(Delayed Data from NYSE)
$97.11 USD
-0.32 (-0.33%)
Updated May 15, 2024 04:00 PM ET
After-Market: $97.08 -0.03 (-0.03%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$97.11 USD
-0.32 (-0.33%)
Updated May 15, 2024 04:00 PM ET
After-Market: $97.08 -0.03 (-0.03%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth B Momentum A VGM
Zacks News
Can Molecular Diagnostics Drive Myriad's (MYGN) Q2 Earnings?
by Zacks Equity Research
Myriad (MYGN) likely to deliver solid Q2 results on the diversified Molecular Diagnostics portfolio with products like GeneSight, EndoPredict, BRACAnalysis CDx and Prolaris tests.
Cigna (CI) Poised to Beat Q4 Earnings on Revenue Growth
by Zacks Equity Research
Cigna's (CI) Q4 results are likely to gain from increase in revenues and membership.
Zacks.com featured expert Kevin Matras highlights: American Airlines, ArcBest, AmerisourceBergen, Cardinal Health and CVS Health
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: American Airlines, ArcBest, AmerisourceBergen, Cardinal Health and CVS Health
5 Stocks in Focus After Recent Broker Rating Upgrades
by Zacks Equity Research
The guidance to design a winning portfolio comes from brokers given their thorough understanding of the stock market.
Zacks.com featured highlights include: ArcBest, American Airlines, Cardinal, Century Aluminum and CVS
by Zacks Equity Research
Zacks.com featured highlights include: ArcBest, American Airlines, Cardinal, Century Aluminum and CVS
5 Broker Favorite Stocks to Watch Out For
by Zacks Equity Research
The task of designing one's portfolio to include potential outperformers is not an easy one. Broker advice is necessary to design a winning portfolio.
Should Value Investors Pick Cardinal Health (CAH) Stock Now?
by Zacks Equity Research
Let's see if Cardinal Health, Inc. (CAH) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Cardinal (CAH) Down 4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Cardinal Health (CAH) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Cardinal Health (CAH) stock is a good choice for value-oriented investors right now from multiple angles.
Cardinal Health to Highlight Cost-Control Approach in ASHP
by Zacks Equity Research
Cardinal Health (CAH) helps hospitals identify hidden savings, improve patient outcomes and drive supply chain efficiencies.
Company News For Nov 8, 2018
by Zacks Equity Research
Companies In The News Are: CAH,DHI,TRIP,WYNN
Cardinal Health (CAH) Surpasses Earnings Estimates in Q1
by Nabaparna Bhattacharya
Cardinal Health (CAH) Q1 results benefit from strong sales in the Pharmaceutical and the Medical segments.
Cardinal Health (CAH) Beats on Earnings & Revenues in Q1
by Zacks Equity Research
Cardinal Health's (CAH) solid segmental performance buoys optimism. FY19 view reiterated.
Earnings Preview: Cardinal Health (CAH) Q1 Earnings Expected to Decline
by Zacks Equity Research
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Cardinal Health's (CAH) Q1 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) likely to gain from solid Pharmaceutical revenues in fiscal Q1; medical-gloves sub-segment likely to be soft.
New Strong Sell Stocks for October 17th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Why Is Cardinal (CAH) Up 0.9% Since Last Earnings Report?
by Zacks Equity Research
Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cardinal Health Product Spectrum Broad, Competition Rife
by Zacks Equity Research
Cardinal Health's (CAH) strategic buyouts lend it a competitive edge; the Cordis unit lacks luster.
Cardinal Health (CAH) Surpasses Earnings Estimates in Q4
by Zacks Equity Research
Cardinal Health (CAH) witnesses strong Q4, owing to strong sales at Pharmaceutical and the Medical segments. It provides an impressive FY19 view.
Cardinal Health (CAH) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 8.60% and 2.32%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Stock Earnings on Aug 6: CAH, HSIC & More
by Zacks Equity Research
The Medical product market gains momentum owing to the recent two-year suspension of the controversial 2.3% Medical Device tax.
3 Dental Stocks to Top Earnings Estimates This Season
by Zacks Equity Research
On upbeat consumer sentiment and increased business investments, the dental supplies industry appears to be in the pink of health now.
Can Solid European Sales Boost Inogen (INGN) in Q2 Earnings?
by Zacks Equity Research
Strong performance in Europe is likely to boost Inogen's (INGN) top line in Q2. However, decline rental-revenues is a concern.
Options Traders Expect Huge Moves in Cardinal Health (CAH) Stock
by Zacks Equity Research
Cardinal Health (CAH) needs investors to pay close attention to the stock based on moves in the options market lately.
What's in Store for Cardinal Health (CAH) in Q4 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) is likely to witness solid growth in the core Pharmaceutical segment in Q4 results. However, lackluster performance in the Cordis unit is likely to mar prospects.